GASTER control® — European MedTech

Modulating satiety perception through non-invasive biomechanical innovation

A CE-marked medical device designed to support appetite regulation by targeting the mechanical component of satiety through controlled extra-parietal compression to the epigastric region.

CE-marked medical device
Prescription only
Brevet déposé

A mechanical approach to appetite regulation

GASTER control® applies controlled extra-parietal compression to the epigastric region, targeting the mechanical component of satiety. No pharmacological action, no internal device, no surgery — a purely external, adjustable, and reversible approach designed for daily use.

"Does not create satiety, but modulates the conditions in which it is perceived."

To understand this mechanism, it is essential to consider satiety within the broader context of appetite regulation. Understanding the role of satiety

Adjustable
User-controlled compression adapted to individual morphology and tolerance
Non-invasive
Fully external, no contact with internal structures, no pharmacological mechanism
Meal-integrated
Designed for use before, during, and after meals in real-life conditions

The Extra-Parietal Balloon (BEP™)

An inflatable biomechanical structure designed for controlled application to the epigastric region, engineered for comfort, reproducibility, and daily wearability.

BEP™ — Patent pending

A complementary tool within structured care pathways

GASTER control® is designed for integration alongside nutritional guidance, behavioral support, and pharmacological or surgical strategies — not as a standalone treatment.

GASTER control® — Abdominal support belt with integrated BEP™ compression module
Bariatric pathway

Pre-operative support and post-operative management of weight regain within surgical care trajectories.

GLP-1 transition

Support during dose reduction, treatment discontinuation, or as a non-pharmacological relay.

First-line option

Selected patients (BMI 27–30) not eligible for GLP-1 therapies, or seeking a non-invasive approach.

This approach can notably support transitions related to GLP-1 therapies.

Explore the role of GLP-1 therapies in appetite regulation
Full clinical information for prescribers

Early behavioral observations

91%
Spontaneous portion reduction
81%
Earlier satiety perception
3–6%
Weight reduction
0
Serious adverse events
Exploratory feasibility observation. These findings are hypothesis-generating and do not constitute proof of clinical efficacy. A multicentric observational registry is underway.
See current clinical evidence
Woman wearing the GASTER control® device in daily life
Man wearing the GASTER control® device in daily life
Illustrative photos

A structured clinical pathway

GASTER control® is currently undergoing multicentric observational evaluation (GC-REG-01) to document usage, tolerance, and behavioral outcomes in routine clinical practice.

~50 participants, BMI 25–40, 8-week follow-up with structured dietitian support. Data centralized on an HDS-certified platform (Obeli), with full GDPR compliance.

Multicentric registry currently enrolling
Scientific committee
MN
Dr Marius Nedelcu
Coordinating investigator — Bariatric surgeon
LM
Dr Ludivine Muzard
Nutritionist
AS
Dr Antoine Sina
Bariatric surgeon
AR
Dr Anthony Rouers
Bariatric surgeon
GC
Dr Gianfranco Calandra
Bariatric surgeon
ID
Pr Ibrahim Dagher
Investigating physician — Professor of Surgery

About GASTER Technology

GASTER Technology Limited is a Malta-based European medical device company. We develop GASTER control® as a complement to existing therapies — GLP-1 receptor agonists, bariatric surgery, dietary and behavioral support — within structured care pathways across Europe.

Established in Valletta, Malta Corporate registration C 84832 — EU jurisdiction
CE-marked under MDR EU 2017/745 Class I medical device — EUDAMED SRN MT-MF-000047377
Operations across European markets Malta, France, with planned UK and DACH expansion in 2027
Learn more about our company

How can we work together?

GASTER control® is open to collaboration across clinical, commercial, and industrial environments.

Healthcare professional

Clinical documentation, prescribing information, patient selection guidance, and training materials.

Access clinical resources
Distribution partner

Exclusive distribution, licensing agreements, and market-specific regulatory adaptation.

Explore partnership models
OEM integration

Integrate the BEP™ technology into your own wearable devices, medical textiles, or health platforms.

Discuss integration

A non-invasive biomechanical approach supporting the perception of satiety signals. Grounded in physiology, designed for clinical integration, and under continuous scientific evaluation.